Full Text
PMS24 LOWER HIP FRACTURE RATES IN THE FIRST YEAR OF THERAPY TRANSLATE INTO FAVORABLE COST-EFFECTIVENESS FOR RISEDRONATE VS. GENERIC ALENDRONATE AMONG HIGH RISK PATIENTS

Abstract

Authors

MF Thompson MK Pasquale DT Grima

Back to Volume 12, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×